(Q34296114)

English

Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapa

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 August 2017

Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapa (English)

1 reference

Europe PubMed Central

1 August 2017

metastatic breast cancer

1 reference

based on heuristic

inferred from title

author name string

Binghe Xu

1

1 reference

Europe PubMed Central

1 August 2017

Zhongzhen Guan

2

1 reference

Europe PubMed Central

1 August 2017

Zhenzhou Shen

3

1 reference

Europe PubMed Central

1 August 2017

Zhongshen Tong

4

1 reference

Europe PubMed Central

1 August 2017

Zefei Jiang

5

1 reference

Europe PubMed Central

1 August 2017

Junlan Yang

6

1 reference

Europe PubMed Central

1 August 2017

Michelle DeSilvio

7

1 reference

Europe PubMed Central

1 August 2017

Mark Russo

8

1 reference

Europe PubMed Central

1 August 2017

Meggan Leigh

9

1 reference

Europe PubMed Central

1 August 2017

Catherine Ellis

10

1 reference

Europe PubMed Central

1 August 2017

publication date

24 July 2014

1 reference

Europe PubMed Central

1 August 2017

Breast Cancer Research

1 reference

Europe PubMed Central

1 August 2017

16

1 reference

Europe PubMed Central

1 August 2017

405

1 reference

Europe PubMed Central

1 August 2017

4

1 reference

Europe PubMed Central

1 August 2017

copyright license

Creative Commons Attribution 4.0 International

24 July 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

https://scigraph.springernature.com/pub.10.1186/s13058-014-0405-y

0 references

Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187249

6 July 2018

Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187249

6 July 2018

Comprehensive molecular portraits of human breast tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187249

6 July 2018

Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187249

6 July 2018

PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187249

6 July 2018

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187249

6 July 2018

Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187249

6 July 2018

Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187249

6 July 2018

Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187249

6 July 2018

Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187249

6 July 2018

Deconstructing the molecular portraits of breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187249

6 July 2018

Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187249

6 July 2018

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187249

6 July 2018

Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187249

6 July 2018

PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187249

6 July 2018

Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187249

6 July 2018

PIK3CA mutation associates with improved outcome in breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187249

6 July 2018

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187249

6 July 2018

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187249

6 July 2018

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187249

6 July 2018

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187249

6 July 2018

Exploiting the PI3K/AKT pathway for cancer drug discovery

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187249

6 July 2018

Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187249

6 July 2018

Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187249

6 July 2018

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187249

6 July 2018

Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas.

1 reference

https://api.crossref.org/works/10.1186%2FS13058-014-0405-Y

21 January 2018

Genetic alterations and oncogenic pathways associated with breast cancer subtypes

1 reference

https://api.crossref.org/works/10.1186%2FS13058-014-0405-Y

21 January 2018

Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy

1 reference

https://api.crossref.org/works/10.1186%2FS13058-014-0405-Y

21 January 2018

PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab.

1 reference

https://api.crossref.org/works/10.1186%2FS13058-014-0405-Y

21 January 2018

Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187249

28 October 2018

Erratum: Integrated genomic analyses of ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1186%2FS13058-014-0405-Y

21 January 2018

Identifiers

10.1186/S13058-014-0405-Y

1 reference

Europe PubMed Central

1 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34296114&oldid=1949711644"